Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Craig Gordon
AddedApr 2, 2024
UpdatedMay 31, 2026
Craig Gordon

Craig Gordon

Founder & CEO, GordonMD Global Investments

CrunchbaseLinkedIn

Craig Gordon's Career

GordonMD Global Investments
GordonMD Global Investments

Beverly Hills, CA, US

Founder & CEO· C-Suite · Management
Spotlight Therapeutics
Spotlight Therapeutics

Hayward, CA, US

Board Member· Board
SalioGen Therapeutics
SalioGen Therapeutics

Cambridge, MA, US

Board Member· Board
Flare Therapeutics
Flare Therapeutics

Cambridge, MA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Craig Gordon's Career

GordonMD Global Investments
GordonMD Global Investments
Investment Firm72021Beverly Hills, CA, US
Founder & CEO· C-Suite · Management
Spotlight Therapeutics
Spotlight Therapeutics
Series B$80.7M312017Hayward, CA, US
Board Member· Board

Leadership at Spotlight Therapeutics

Jacob CornJacob CornFounder
Mary Haak-FrendschoMary Haak-FrendschoBoard Member
SalioGen Therapeutics
SalioGen Therapeutics
Series B$135M912020Cambridge, MA, US
Board Member· Board

Leadership at SalioGen Therapeutics

Ray TabibiazarRay TabibiazarBoard Member
Jason ColeJason ColeBoard Member
Joseph HigginsJoseph HigginsFounder

Similar to SalioGen Therapeutics

Intergalactic TherapeuticsIntergalactic TherapeuticsCambridge, MA, USGene Therapyest. 2020Intergalactic TherapeuticsCambridge, MA, US · est. 2020

Intergalactic Therapeutics: Pioneering the future of non-viral gene therapy for patients.

Series A · $75M41
Exegenesis BioExegenesis BioLansdale, PA, USGene Therapyest. 2019Exegenesis BioLansdale, PA, US · est. 2019

Exegenesis: A global leader in gene therapy, innovating new medicines for China and worldwide.

Series B · $10M17
eGenesiseGenesisCambridge, MA, USGene Editing, Organsest. 2015eGenesisCambridge, MA, US · est. 2015

eGenesis: Revolutionizing transplantation with a gene editing platform for human-compatible organs.

Series C · $265M105
Flare Therapeutics
Flare Therapeutics
Series C$290M632021Cambridge, MA, US
Board Member· Board

Recent news

Flare Therapeutics Secures $85M in Insider-Led Series C Financing and Appoints Anna Protopapas as Chief Executive OfficerFlare Therapeutics · 2026
Flare Therapeutics Appoints Stephen L. Eck, M.D., Ph.D., as Chief Medical OfficerFlare Therapeutics · 2026
Flare Therapeutics Presents Correlative Biomarker Analysis from the FX-909 Phase 1A Clinical Study at SITC 2025 40th Anniversary Annual MeetingFlare Therapeutics · 2025

Leadership at Flare Therapeutics

Stephen EckStephen EckChief Medical Officer
Anna ProtopapasAnna ProtopapasCEO
Irena MelnikovaIrena MelnikovaBoard Member
Abbie CelnikerAbbie CelnikerBoard Member
Fraydoon RastinejadFraydoon RastinejadCo-Founder
Jakob LovenJakob LovenBoard Member

People Similar to Craig Gordon

Jay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakWillix HalimWillix HalimCEO · BukalapakChi-hyung SongChi-hyung SongBoard Member · DunamuLee Sirg-OoLee Sirg-OoCEO · DunamuIn-hyuk ChoiIn-hyuk ChoiCEO · Naver FinancialWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiBenjamin GordonBenjamin GordonBoard Member · Greenscreens.aiMark J SchwartzMark J SchwartzBoard Member · Palladin Consumer Retail PartnersLaurent GhouziLaurent GhouziFounder · The Merchant ClubStephen GrabowskiStephen GrabowskiCo-Founder & CEO · Axel TravelLawrence Eric GolubLawrence Eric GolubBoard Member · Golub CapitalGordon Hirsch WilsonGordon Hirsch WilsonCo-Founder & CEO · Rain Neuromorphics